DOCSLIB.ORG

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs molecules Review Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs Chinh Tran-To Su 1, Darius Wen-Shuo Koh 1 and Samuel Ken-En Gan 1,2,* 1 Antibody & Product Development Lab, Bioinformatics Institute, A*STAR, Singapore 138671, Singapore 2 p53 Laboratory, A*STAR, Singapore 138648, Singapore * Correspondence: [email protected]; Tel.: +65-6478-8417; Fax: +65-6478-9047 Academic Editor: Keykavous Parang Received: 23 August 2019; Accepted: 4 September 2019; Published: 6 September 2019 Abstract: HIV protease inhibitors against the viral protease are often hampered by drug resistance mutations in protease and in the viral substrate Gag. To overcome this drug resistance and inhibit viral maturation, targeting Gag alongside protease rather than targeting protease alone may be more efficient. In order to successfully inhibit Gag, understanding of its drug resistance mutations and the elicited structural changes on protease binding needs to be investigated. While mutations on Gag have already been mapped to protease inhibitor resistance, there remain many mutations, particularly the non-cleavage mutations, that are not characterized. Through structural studies to unravel how Gag mutations contributes to protease drug resistance synergistically, it is thus possible to glean insights to design novel Gag inhibitors. In this review, we discuss the structural role of both novel and previously reported Gag mutations in PI resistance, and how new Gag inhibitors can be designed. Keywords: HIV-1 Gag; Gag inhibitors; protease; protease inhibitors; drug resistance mutations; drug design 1. Introduction Many anti-HIV drugs interfere directly with the viral life cycle by targeting key viral enzymes [1], e.g., reverse transcriptase inhibitors [2,3], integrase inhibitors [4,5], and protease inhibitors [6,7]. While such efforts are already hampered by the emergence of drug resistance mutations in the enzymes (e.g., in [8]), the scenario further worsens when viral enzyme substrates, such as Gag (HIV protease substrate), are found to synergistically contribute to drug resistance. Gag and protease play key roles in the viral maturation process [9] where the immature HIV virion matures into the infectious virion after budding from the infected cell for the next replication cycle. Proteolysis of Gag by protease occurs during the early stage of this maturation (Figure1A), in which the intact full length Gag precursor polyprotein is cleaved by the viral protease into functional subunits [9]. To inhibit this proteolysis, protease inhibitors (PIs) block protease activity in a competitive manner with Gag for protease binding [10]. PI-resistant mutations have been reported on Protease [11–13] and Gag [14–18] alone, or concurrently on both Protease and Gag [17,19–22], revealing an enzyme-substrate synergy to overcome PIs [23] (Figure1B). Expectedly, Gag cleavage site mutations contribute directly to PI resistance [ 24], while non- cleavage site mutations contribute to drug resistance by compensating for the loss of viral fitness [22,25,26] that resulted when protease accumulates drug resistant mutations reducing its proteolytic functions. As Gag is a larger protein than protease, and mutations (both cleavage and non-cleavage) can contribute to PI resistance, there is thus a need to study the mechanisms to how these mutations work Molecules 2019, 24, 3243; doi:10.3390/molecules24183243 www.mdpi.com/journal/molecules Molecules 2018, 23, x FOR PEER REVIEW 2 of 14 MoleculesAs 2019Gag, 24is, a 3243 larger protein than protease, and mutations (both cleavage and non-cleavage)2 ofcan 13 contribute to PI resistance, there is thus a need to study the mechanisms to how these mutations work in synergy with protease. Such studies will unravel potential weak points to which Gag can be in synergy with protease. Such studies will unravel potential weak points to which Gag can be targeted targeted against, opening more opportunities in drug design. against, opening more opportunities in drug design. FigureFigure 1. 1. AnAn overview overview of of the the Gag Gag and and Protease Protease relationship. relationship. (A) (A) A A schematic schematic of of the the early early stage stage of of viral viral maturationmaturation where where HIV-1 HIV-1 Protease cleaves Gag Gag into into th thee functional functional subunits: subunits: Ma Matrixtrix (MA), (MA), capsid capsid (CA), (CA), nucleocapsidnucleocapsid (NC), (NC), p6, p6, and and two two spacer spacer peptides peptides p1 p1 and and p2. p2. (B) (B) To To inhibit inhibit viral viral maturation, maturation, protease protease inhibitorsinhibitors (PIs(PIs iningreen green) are) are used used to competitively to competitively inhibit inhibit protease protease binding binding of Gag. PIof resistantGag. PI mutationsresistant mutationsare denoted are by denoted colored by stars, colored where stars, those where in the those protease in the catalytic protease site catalytic are in blue site, while are in those blue, inwhile Gag thoseare red infor Gag cleavage are red sites,for cleavage and purple sites,for and non-cleavage purple for non-cleavage sites. sites. 2.2. Possible Possible Targets Targets in in Gag Gag TheThe Gag Gag polyprotein polyprotein consists consists of of components components matrix matrix (MA), (MA), capsid capsid (CA), (CA), nucleocapsid nucleocapsid (NC), (NC), p6, p6, andand two two spacer spacer peptides p1 and p2. The The MA MA subuni subunit,t, located located at at the the N-terminus, N-terminus, is is essential essential for for targetingtargeting Gag Gag to to the the cell cell membrane, membrane, while while the the CA CA forms forms a a shell shell to to protect protect the the viral viral RNA RNA genome genome and and otherother core proteinsproteins duringduring maturation. maturation. The The NC NC is is responsible responsibl fore for RNA RNA packing packing and and encapsidation encapsidation [27] [27]while while the twothe two spacer spacer peptides peptides p1 and p1 and p2 regulate p2 regula thete ratethe rate and and the sequentialthe sequential cleavage cleavage process process of Gag of Gagby protease by protease [28]. [28]. This This process process of viral of assemblyviral assembly is complemented is complemented by viral by buddingviral budding moderated moderated by the bysmall the Proline-richsmall Proline-rich p6. Mutations p6. Mutations at either at either the N-terminal the N-terminal or C-terminal or C-terminal of these of these core proteinscore proteins were werereported reported to block to viralblock assembly viral assembly and impair and Gagimpair binding Gag tobinding plasma to membrane, plasma membrane, thereby inhibiting thereby inhibitingviral budding viral [ 27budding]. [27]. SinceSince the the Gag Gag cleavage cleavage sites sites do do not not share share a a consen consensussus sequence sequence (Figure (Figure 22),), the recognition ofof the cleavagecleavage sites sites by by protease protease is is like likelyly to to be be based based on on their their asymmetric asymmetric three-dimensional three-dimensional structures structures [29] [29] thatthat would would fit fit into into the the substrate-binding substrate-binding pocket pocket of of protease protease [30]. [30]. The The cleavage cleavage of of these these scissile scissile bonds bonds (seven-residue(seven-residue peptide peptide sequences sequences unique unique for for each each cleavage cleavage site) site) are are highly highly regulated regulated and and occur occur at at differingdiffering rates [24,28,31]. [24,28,31]. The The first first cleavage cleavage occurs occurs at at the the site site betw betweeneen the the p2 p2 peptide peptide and and NC NC domain domain (Figure(Figure 22),), followedfollowed byby thethe MAMA fromfrom CA–p2CA–p2 atat aa raterate thatthat isis ~14-fold~14-fold slowerslower thanthan thatthat ofof thethe firstfirst cleavage,cleavage, before before proceeding proceeding to to release release p6 p6 from from the the NC-p1 domain (at a rate ~9-fold slower slower than than the the Molecules 2019, 24, 3243 3 of 13 Molecules 2018, 23, x FOR PEER REVIEW 3 of 14 firstfirst cleavage). cleavage). At At the the last step, the two spacerspacer peptidespeptides p1p1 and and p2 p2 are are cleaved cleaved from from NC-p1 NC-p1 and and CA–p2 CA– p2at ratesat rates ~350-fold ~350-fold and and ~400-fold, ~400-fold, respectively, respectively, slower slower than than the the initial initial cleavage cleavage [24 [24,28,30,31].,28,30,31]. FigureFigure 2. 2. TheThe sequential sequential Gag Gag proteolysis proteolysis by by Protease. Protease. The The cleavage cleavage sites sites are are marked marked by by the the 7-residues, 7-residues, alongalong with thethe estimated estimated cleavage cleavage rates rates [28 ][28] marked mark byed arrows. by arrows. For easy For comparison, easy comparison, the initial the cleavage initial cleavagesite rate issite set rate to the is valueset to of the 1, whilevalue theof 1, other while cleavage the other site valuescleavage depict site thevalues reduced depict normalized the reduced rate. normalizedThe cleavage rate. site The sequences cleavage are site colored sequences based are on colored their physicochemical based on their properties,physicochemical e.g., hydrophobic properties, e.g.,(black hydrophobic), charged (positive: (black), chargedblue, negative: (positive:red blue), polar, negative: (other red colors),), polar and (other varied colors), in text and sizes varied based in text
Load more

Recommended publications
  • Download Article PDF/Slides
    Kan Lu, PharmD New Antiretrovirals for Based on a presentation at prn by Roy M. Gulick, md, mph the Treatment of HIV: Kan Lu, PharmD | Drug Development Fellow University of North Carolina School of Pharmacy Chapel Hill, North Carolina The View in 2006 Roy M. Gulick, md, mph Reprinted from The prn Notebook® | october 2006 | Dr. James F. Braun, Editor-in-Chief Director, Cornell Clinical Trials Unit | Associate Professor of Medicine, Meri D. Pozo, PhD, Managing Editor. Published in New York City by the Physicians’ Research Network, Inc.® Weill Medical College of Cornell University | New York, New York John Graham Brown, Executive Director. For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©october 2006 substantial progress continues to be made in the arena of cokinetics and a long extracellular half-life of approximately 10 hours antiretroviral drug development. prn is again proud to present its annual (Zhu, 2003). During apricitabine’s development, a serious drug interac- review of the experimental agents to watch for in the coming months and tion with lamivudine (Epivir) was noted. Although the plasma years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a long- concentrations of apricitabine were unaffected by coadministration of time friend of prn, and no stranger to the antiretroviral development lamivudine, the intracellular concentrations of apricitabine were reduced pipeline. by approximately sixfold. Additionally, the 50% inhibitory concentration To date, twenty-two antiretrovirals have been approved by the Food (ic50) of apricitabine against hiv with the M184V mutation was increased and Drug Administration (fda) for the treatment of hiv infection.
    [Show full text]
  • Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment
    Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 ▪ Pipeline is robust! ▪ Several drugs, coformulations, and biologics in late-stage development and Phase I trials ▪ Trends are clear ▪ Maximizing safety and efficacy of three-drug regimens ▪ Validating two-drug regimens as durable maintenance therapy and, potentially, for PLWHIV starting treatment for the first time ▪ Advancing long-acting and extended release products ▪ Development new drugs and biologics for multi-drug/class-resistant HIV ▪ Cost considerations in high- and middle-income countries Compound Class/Type Company Status DRUGS Isentress HD INSTI Merck FDA Approved 5/30/17 Bictegravir plus TAF/FTC INSTI plus NtRTI & NRTI Gilead Phase III; mid-2018 approval Doravirine (plus TDF/3TC) NNRTI (plus NtRTI & NRTI) Merck Phase III; mid-2018 approval Darunavir plus cobicistat, PI plus PK booster, NtRTI & Janssen Phase III; mid-2018 approval TAF & FTC NRTI Dolutegravir plus rilpivirine INSTI plus NNRTI ViiV/Jansse Phase III; early 2018 approval n Dolutegravir plus lamivudine INSTI plus NRTI ViiV Phase III; late 2018 approval BIOLOGICS Ibalizumab Entry Inhibitor TaiMed Phase III; late 2017 or early Biologics 2018 Compound Class/Type Company Status DRUGS LA Cabotegravir + INSTI + NNRTI ViiV/ Phase III LA Rilpivirine Janssen Albuvirtide Fusion Inhibitor Frontier Phase III; China is primary Biologics launch target Fostemsavir CD4 attachment inhibitor ViiV Phase III Elsulfavirine
    [Show full text]
  • 14-258 Phrma HIV/AIDS2014 0819.Indd
    2014 MEDICINES IN DEVELOPMENT REPORT HIV/AIDS PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention Medicines and Vaccines in Globally, approximately 35 million people effective therapies, and preventative Development for HIV Infection are infected with human immunodefi - vaccines. These medicines and vaccines ciency virus (HIV), the virus that causes are either in clinical trials or awaiting Application acquired immune defi ciency syndrome review by the U.S. Food and Drug Submitted (AIDS). However, new infections have Administration (FDA). Phase III dropped by 38 percent since 2001, Phase II The 44 medicines and vaccines in the according to UNAIDS, the Joint United Phase I development pipeline include: Nations Programme on HIV/AIDS. • A fi rst-in-class medicine intended to In the United States, more than 25 prevent HIV from breaking through 1.1 million people are living with HIV the cell membrane. and 15.8 percent of those are unaware they are infected, according to the • A cell therapy that modifi es a U.S. Centers for Disease Control and patient’s own cells in an attempt to Prevention (CDC). Although the U.S. make them resistant to HIV. HIV/AIDS-related death rate has fallen 16 by more than 80 percent since the introduction of antiretroviral therapies in Contents 1995, new HIV infections have stabilized HIV Medicines and Vaccines in at approximately 50,000 each year, Development ......................................2 according to the CDC. Incremental Innovation in HIV/AIDS Treatment .......................... 4 Since AIDS was fi rst reported in 1981, Access to HIV/AIDS Medicines in nearly 40 medicines have been approved Exchange Plans ...................................5 to treat HIV infection in the United Facts About HIV/AIDS ........................7 States.
    [Show full text]
  • Download Article PDF/Slides
    Roy M. Gulick, MD, MPH View from the Pipeline: Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine The 2005 Review of Experimental Weill Cornell Medical College Antiretrovirals New York, New York Summary by Tim Horn Reprinted from The prn Notebook® | june 2005 | Dr. James F. Braun, Editor-in-Chief | Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.® | John Graham Brown, Executive Director Edited by Sheldon T. Brown, md, For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©june 2005 and Martin Markowitz, md there are 20 unique medications approved for the treatment of maintaining undetectable hiv-rna levels while taking standard regi- hiv infection. Despite this impressive number, there is an indisputable mens, added 200 mg d-d4fc to their therapies for ten days (and two oth- need for new anti-hiv compounds that have potent and durable effica- er others added d-d4fc placebos). cy profiles, unique resistance patterns, patient-friendly dosing schedules, The mean reduction in viral load among the treatment-naive pa- and minimal toxicities. What follows is an overview of some the newest tients in the three treatment groups ranged from 1.67 log10 copies/mL to antiretroviral contenders, discussed by Dr. Roy M. Gulick during a re- 1.77 log10 copies/mL (see Figure 1). Among the treatment-experienced pa- cent meeting of the Physicians’ Research Network. tients, the mean reduction in viral load was 0.8 log10 copies/mL. Seven of eight treatment-naive patients (in the 200 mg d-d4fc group) and four of eight treatment-experienced patients achieved undetectable viral loads (<400 copies/mL) after ten days of therapy.
    [Show full text]
  • What's in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV And
    What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials by Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed edited by Mark Harrington & Bob Huff Treatment Action Group New York, NY, USA July 2005 e thymidine • BI-201 • Racivir (PSI 5004) • TMC-278 • Diarylpyrimidine (DAPY) • 640385 • Reverset (D-D4FC) • JTK-303 • UK-427 (maraviroc) • Amdoxovir • AMD-070 • Vicriviroc LIPO-5 • GTU-Multi-HIV • pHIS-HIV-B • rFPV-HIV-B • ADMVA • GSK Protein HIV Vaccine TBC-M335 (MVA) • TBC-F357 (FPV) • TBC-F349 (FPV) • LIPO-4T (LPHIV-1) • LFn-p24 • H G • Oligomeric gp140/MF59 • VRC-HIVDNA-009-00-VP • PolyEnv1 • ISS P-001 • EP HIV- • BufferGel • Lactin-V • Protected Lactobacilli in combination with BZK • Tenofovir/PMPA G ulose acetate/CAP) • Lime Juice • TMC120 • UC-781 • VivaGel (SPL7013 gel) • ALVAC Ad5 • Autologous dendritic cells pulsed w/ALVAC • Autologous dendritic cell HIV vaccination x • Tat vaccine • GTU-nef DNA vaccine • Interleukin-2 (IL-2) • HE2000 • Pegasys (peginter L-4/IL-13 trap • Serostim • Tucaresol • MDX-010 anti-CTLA4 antibody • Cyclosporine A • 496 • HGTV43 • M87o • Vertex • VX-950 • Idenix • Valopicitabine (NM283) • JTK-003 mplant • Albuferon • Celgosivir (MBI-3253) • IC41 • INN0101 • Tarvicin • ANA971 (oral) floxacin, Tequin • J, TMC207 (ex R207910) • LL-3858 • M, moxifloxacin, Avelox • PA-824 Acknowledgements. Thanks to our intrepid editors, Bob Huff, copy-editor Andrea Dailey, and proof-reader Jen Curry, to awesome layout expert Lei Chou, to webmaster Joel Beard, to Joe McConnell for handling administrative matters related to the report, and most of all to the board and supporters of TAG for making our work possible.
    [Show full text]
  • Can the Further Clinical Development of Bevirimat Be Justified?
    SwatiCE: Swati; QAD/201969; Total nos of Pages: 2; QAD 201969 EDITORIAL COMMENT Can the further clinical development of bevirimat be justified? Mark A. Wainberga and Jan Albertb AIDS 2010, 24:000–000 Keywords: bevirimat, protease inhibitor resistance HIV-infected patients who fail standard therapeutic Not surprisingly, however, HIV resistance against BVM regimens are in need of new drugs that will remain has been selected in tissue culture. Mutations responsible active against drug-resistant viral variants. There is a for resistance have been identified within flanking constant need to develop new compounds that will not be sequences of the p24/p2 cleavage site and have been compromised by problems of cross-resistance, as so often confirmed as possessing biological relevance by site- occurs among members of the same family of drugs, for directed mutagenesis [3]. These mutations can sometimes example, nucleoside reverse transcriptase inhibitors interfere with the ability of BVM to bind to its target, (NRTIs), nonnucleoside reverse transcriptase inhibitors although, in most cases, increased cleavage efficiency at (NNRTIs), and protease inhibitors. Indeed, successful the p24/p2 junction may also occur [3,4]. second-line and salvage regimens will commonly include members of drug classes to which a patient has not Recent results have revealed that naturally occurring previously been exposed, for example, a protease inhibi- polymorphisms located within p2, close to the p24 tor and an integrase strand transfer inhibitor (INSTI) in cleavage site, may be present in some individuals, the case of an individual who began therapy with two resulting in lower BVM anti-HIV efficacy. In addition, NRTIs and a NNRTI, as well as the use of fusion clinical investigators have long suspected that BVM might inhibitors, for example, enfuvirtide, and CCR5 antago- potentially be less effective in the treatment of patients nists, for example, maraviroc.
    [Show full text]
  • Antiviral Activity Exerted by Natural Products Against Human Viruses
    viruses Review Antiviral Activity Exerted by Natural Products against Human Viruses Maria Musarra-Pizzo 1, Rosamaria Pennisi 1,2 , Ichrak Ben-Amor 1,3, Giuseppina Mandalari 1,* and Maria Teresa Sciortino 1,* 1 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale SS. Annunziata, 98168 Messina, Italy; [email protected] (M.M.-P.); [email protected] (R.P.); [email protected] (I.B.-A.) 2 Shenzhen International Institute for Biomedical Research, 1301 Guanguang Rd. 3F Building 1-B, Silver Star Hi-Tech Park Longhua District, Shenzhen 518116, China 3 Unit of Biotechnology and Pathologies, Higher Institute of Biotechnology of Sfax, University of Sfax, Sfax 3029, Tunisia * Correspondence: [email protected] (G.M.); [email protected] (M.T.S.); Tel.: +39-090-6767-5217 (G.M. & M.T.S.) Abstract: Viral infections are responsible for several chronic and acute diseases in both humans and animals. Despite the incredible progress in human medicine, several viral diseases, such as acquired immunodeficiency syndrome, respiratory syndromes, and hepatitis, are still associated with high morbidity and mortality rates in humans. Natural products from plants or other organisms are a rich source of structurally novel chemical compounds including antivirals. Indeed, in traditional medicine, many pathological conditions have been treated using plant-derived medicines. Thus, the identification of novel alternative antiviral agents is of critical importance. In this review, we summarize novel phytochemicals with antiviral activity against human viruses and their potential application in treating or preventing viral disease. Citation: Musarra-Pizzo, M.; Pennisi, R.; Ben-Amor, I.; Mandalari, G.; Keywords: viral infections; natural bioactive compounds; novel antiviral drugs; drug resistance Sciortino, M.T.
    [Show full text]
  • Treatmen+ (E) HTB: 2019 Vol 20 No 4 Bulletin
    ISSN 1472-4863 hiv treatmen+ (e) HTB: 2019 vol 20 no 4 bulletin 28 March 2019: no 4 CROI 2019: second reports C O N T E N T S EDITORIAL 2 • Integrase inhibitors and neural tube defects: SUPPLEMENTS 2 more data still needed • U=U resources for UK clinics: free posters, • Double-dose levonorgestrel implant does not postcards and factsheets completely overcome interaction with efavirenz i-BASE APPEAL 2 • Efavirenz and rifampicin together reduce levels of • i-Base 2019 appeal: we need your help…. injectable contraception CONFERENCE REPORTS 3 • Bedaquiline and delamanid safe when given Conference on Retroviruses and Opportunistic together to treat drug resistant TB Infections (CROI 2019), 4–7 March, 2019 • Isoniazid preventative therapy in HIV positive • Introduction pregnant women not linked to poor outcomes • Maturation inhibitor GSK’232 reduces viral load ANTIRETROVIRALS 11 by –1.5 log at day 10 • Dear Doctor letter: Increased risk of treatment • Capsid inhibitor GS-6297 shows potential for failure and increased risk of mother-to-child 3-monthly injections transmission of HIV infection dues to lower • First phase 1 results from bNAb PGT121 in HIV exposure of elvitegravir and cobicistat during the positive people second and third trimesters of pregnancy • Dolutegravir/3TC dual ART is as effective at FUTURE MEETINGS 12 lowest viral load cut-off as triple therapy in • Conference listing 2019 GEMINI Studies PUBLICATIONS AND SERVICES • Same-day ART in San Francisco: long-term FROM i-BASE 13 follow-up from Rapid-ART clinic ORDER FORM 14 Published by HIV i-Base HIV TREATMENT BULLETIN h-tb EDITORIAL HIV TREATMENT BULLETIN This issue of HTB includes our second set of reports from HTB is published in electronic format by HIV i-Base.
    [Show full text]
  • C07K 16/10 (2006.01) Foster City, California 94404 (US)
    ) ( (51) International Patent Classification: Craig S.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, A61P31/18 (2006.01) C07K 16/10 (2006.01) Foster City, California 94404 (US). REHDER, Doug; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cal¬ (21) International Application Number: ifornia 94404 (US). SCHENAUER, Matthew Robert; c/ PCT/US20 19/040342 o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, (22) International Filing Date: California 94404 (US). SERAFINI, Loredana; c/o Gilead 02 July 2019 (02.07.2019) Sciences, Inc., 333 Lakeside Drive, Foster City, Califor¬ nia 94404 (US). STEPHENSON, Heather Theresa; c/ (25) Filing Language: English o Gilead Sciences, Inc., 333 Lakeside Drive, Foster Ci¬ (26) Publication Language: English ty, California 94404 (US). THOMSEN, Nathan D.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cal¬ (30) Priority Data: ifornia 94404 (US). YU, Helen; c/o Gilead Sciences, Inc., 62/693,642 03 July 2018 (03.07.2018) US 333 Lakeside Drive, Foster City, California 94404 (US). 62/810,191 25 February 2019 (25.02.2019) US ZHANG, Xue; c/o Gilead Sciences, Inc., 333 Lakeside Dri¬ (71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 ve, Foster City, California 94404 (US). Lakeside Drive, Foster City, California 94404 (US). (74) Agent: WAHLSTEN, Jennifer L. et al.; Gilead Sciences, (72) Inventors: BALAKRISHNAN, Mini; c/o Gilead Inc., 333 Lakeside Drive, Foster City, California 94404 Sciences, Inc., 333 Lakeside Drive, Foster City, Califor¬ (US). nia 94404 (US). CARR, Brian A.; c/o Gilead Sciences, (81) Designated States (unless otherwise indicated, for every Inc., 333 Lakeside Drive, Foster City, California 94404 kind of national protection av ailable) .
    [Show full text]
  • Peltophorum Africanum, a Traditional South African Medicinal Plant, Contains an Anti HIV-1 Constituent, Betulinic Acid
    Tohoku J. Exp. Med., 2009, 217Betulinic, 93-99 Acid as an Anti-HIV-1 Constituent of Peltophorum Africanum 93 Peltophorum Africanum, a Traditional South African Medicinal Plant, Contains an Anti HIV-1 Constituent, Betulinic Acid 1 2 1 3 ANDROS THEO, TRACY MASEBE, YASUHIRO SUZUKI, HARUHISA KIKUCHI, 3 4 2 1,5 SHOKO WADA, CHIKWELU LARRY OBI, PASCAL OBONG BESSONG, MOTOKI USUZAWA, 3 1 YOSHITERU OSHIMA and TOSHIO HATTORI 1Laboratory of Emerging Infectious Diseases, Internal Medicine, Graduate School of Medicine, Tohoku University, Sendai, Japan 2Department of Microbiology, University of Venda, Thohoyandou, Limpopo Province, South Africa 3Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan 4Academic and Research Directorate, Walter Sisulu University, Nelson Mandela Drive, Mthatha, Eastern Cape, South Africa 5Japan Foundation for AIDS Prevention, Tokyo, Japan The biodiversity of medicinal plants in South Africa makes them rich sources of leading compounds for the development of novel drugs. Peltophorum africanum (Fabaceae) is a deciduous tree widespread in South Africa. The stem bark has been traditionally employed to treat diarrhoea, dysentery, sore throat, wounds, human immunodeficiency virus/ acquired immune deficiency syndrome (HIV/AIDS), venereal diseases and infertility. To evaluate these ethnobotanical clues and isolate lead compounds, butanol and ethyl acetate extracts of the stem bark were screened for their inhibitory activities against HIV-1 using MAGI CCR5+ cells, which are derived from HeLa cervical cancer cells and express HIV receptor CD4, a chemokine receptor CCR5 and HIV-LTR-β- galactosidase. Bioassay-guided fractionation using silica gel chromatog- raphy was also conducted. The ethyl acetate and butanol extracts of the stem bark of Peltophorum africa- num showed inhibitory activity against HIV-1, CXCR4 (X4) and CCR5 (R5) tropic viruses.
    [Show full text]
  • Antiviral Drugs in the Treatment of Aids: What Is in the Pipeline ?
    October 15, 2007 EU RO PE AN JOUR NAL OF MED I CAL RE SEARCH 483 Eur J Med Res (2007) 12: 483-495 © I. Holzapfel Publishers 2007 ANTIVIRAL DRUGS IN THE TREATMENT OF AIDS: WHAT IS IN THE PIPELINE ? Hans-Jürgen Stellbrink Infektionsmedizinisches Centrum Hamburg ICH, Hamburg, Germany Abstract even targeting immune responses have to be devel- Drug development in the field of HIV treatment is oped. Continued drug development serves the ulti- rapid. New nucleoside analogues (NRTI), non-nucleo- mate goal of normalization of life expectancy. side analogue reverse transcriptase inhibitors (NNR- TI), and protease inhibitors (PI) are currently being in- METHODS vestigated in human trials. Furthermore, inhibitors of HIV attachment, fusion and integrase with novel Drug development in the field of HIV infection is modes of action are being developed, which offer new highly competitive, and a company’s decision to pur- perspectives for the goal of a normalization of life-ex- sue or discontinue the development of a drug is dri- pectancy in HIV-infected individuals. The most ad- ven by economic rather than scientific considerations. vanced compounds likely to become licensed soon in- Of all candidate compounds, only a few reach the lev- clude the NNRTIs rilpivirine and etravirine, the inte- el of trials in humans, and some exhibit lack of effica- grase inhibitors raltegravir and elvitegravir, and mar- cy or toxicity problems at this stage. Some compounds aviroc and vicriviroc, novel inhibitors of the CCR5 also have no obvious advantage over currently avail- chemokine receptor, which functions as the major able ones, so that their development is discontinued.
    [Show full text]
  • Development of a Binding Assay Between the HIV-1 Envelope
    Development of a binding assay between the HIV-1 envelope protein (gp120) and coreceptors CCR5/CXCR4 by Surface Plasmon Resonance : Screening and optimization of viral entry inhibitors Bridgette Janine Connell To cite this version: Bridgette Janine Connell. Development of a binding assay between the HIV-1 envelope protein (gp120) and coreceptors CCR5/CXCR4 by Surface Plasmon Resonance : Screening and optimiza- tion of viral entry inhibitors. Agricultural sciences. Université de Grenoble, 2012. English. NNT : 2012GRENV013. tel-00721774 HAL Id: tel-00721774 https://tel.archives-ouvertes.fr/tel-00721774 Submitted on 30 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITÉ DE GRENOBLE Spécialité : CHIMIE ET SCIENCES DU VIVANT (218) Arrêté ministériel : 7 août 2006 Présentée par Bridgette Janine CONNELL Thèse dirigée par Hugues LORTAT-JACOB préparée au sein du Laboratoire Structure and Activity of GlycosAminoGlycans (SAGAG), Institut de Biologie Structurale (IBS) dans l'École Doctorale Chimie et Sciences du Vivant Développement d’un test d’interaction entre la protéine d’enveloppe du VIH-1 (gp120) et les corécepteurs CCR5/CXCR4 par résonance plasmonique de surface: Criblage et optimisation d’inhibiteurs de l’entrée virale Thèse soutenue publiquement le 16 Mars 2012, devant le jury composé de : Dr.
    [Show full text]